☆ 4.8 Review

Fast-track development of vaccines for SARS-CoV-2: The shots that saved the world

FRONTIERS IN IMMUNOLOGY (2022)

Related references

Note: Only part of the references are listed.

Article Public, Environmental & Occupational Health

Effectiveness of two coronavirus disease 2019 (COVID-19) vaccines (viral vector and inactivated viral vaccine) against severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in a cohort of healthcare workers

Alexandre R. Marra et al.

Summary: This study investigated the real-world effectiveness of the Oxford-AstraZeneca (ChAdOx1) and CoronaVac vaccines against SARS-CoV-2 infection among healthcare workers in Brazil. The results showed that both vaccines significantly prevented COVID-19, but CoronaVac was much less effective. Additionally, both vaccines reduced hospitalizations and the need for mechanical ventilation, and were effective against the dominant gamma variant.

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2023)

Add to Collection

Letter Critical Care Medicine

Tomato flu outbreak in India

Vivek P. Chavda et al.

LANCET RESPIRATORY MEDICINE (2023)

Add to Collection

Letter Oncology

COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer

Cong Zeng et al.

CANCER CELL (2022)

Add to Collection

Editorial Material Immunology

Global impact of delta plus variant and vaccination

Vivek P. Chavda et al.

EXPERT REVIEW OF VACCINES (2022)

Add to Collection

Article Immunology

The race for a COVID-19 vaccine: where are we up to?

Md Kamal Hossain et al.

Summary: The global pandemic of COVID-19 caused by the novel coronavirus strain SARS-CoV-2 has led to millions of deaths and infections, prompting urgent vaccine development efforts. Significant progress has been made with some vaccines receiving emergency use approval, but the emergence of new variants poses ongoing challenges in controlling the pandemic.

EXPERT REVIEW OF VACCINES (2022)

Add to Collection

Letter Virology

Emergence of Omicron third lineage BA.3 and its importance

Perumal A. Desingu et al.

JOURNAL OF MEDICAL VIROLOGY (2022)

Add to Collection

Article Virology

Adverse events following immunization of COVID-19 (Covaxin) vaccine at a tertiary care center of India

Swayam Pragyan Parida et al.

Summary: The study aimed to assess adverse events following COVID-19 vaccine immunization and identify the predictors of these events. The study found that female sex, history of allergic reactions, presence of comorbidities, recent acute infection, and intake of chronic medications were major factors associated with adverse events. Precaution is needed when vaccinating individuals with these risk factors.

JOURNAL OF MEDICAL VIROLOGY (2022)

Add to Collection

Editorial Material Geriatrics & Gerontology

Omicron variant (B.1.1.529) of SARS-CoV-2: Threat for the elderly?

Vivek P. Chavda et al.

MATURITAS (2022)

Add to Collection

Article Medicine, General & Internal

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

A. Jayk Bernal et al.

Summary: This study found that early treatment with molnupiravir reduced the risk of hospitalization or death in at-risk, unvaccinated adults with Covid-19.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Obstetrics & Gynecology

Neutralizing Antibodies and Cytokines in Breast Milk After Coronavirus Disease 2019 (COVID-19) mRNAVaccination

Vignesh Narayanaswamy et al.

Summary: This study found that lactating women who received mRNA-based COVID-19 vaccines exhibited immune responses in their breast milk, which could be transferred to breastfeeding infants. The antibodies in breast milk were able to neutralize the spike protein of SARS-CoV-2 and its variants. This suggests the potential for passive immunity against COVID-19 in breastfed infants.

OBSTETRICS AND GYNECOLOGY (2022)

Add to Collection

Letter Medicine, General & Internal

Some reflections on vaccine research ethics during COVID-19 pandemic

Nanda Gamad et al.

POSTGRADUATE MEDICAL JOURNAL (2022)

Add to Collection

Article Public, Environmental & Occupational Health

Isolation and characterization of SARS-CoV-2 Beta variant from UAE travelers

Pragya D. Yadav et al.

Summary: This study collected samples from travelers and found that SARS-CoV-2 variants are more easily transmitted through international travel. The researchers successfully isolated two strains with high viral RNA loads, which is important for evaluating the protective efficacy of current and upcoming COVID-19 vaccines in India.

JOURNAL OF INFECTION AND PUBLIC HEALTH (2022)

Add to Collection

Review Medicine, General & Internal

Omicron variant (B.1.1.529) of SARS-CoV-2: Mutation, infectivity, transmission, and vaccine resistance

Shi-Yan Ren et al.

Summary: This review summarizes the highly mutated regions, infectivity, transmission, vaccine breakthrough, and antibody resistance of the SARS-CoV-2 variant Omicron. Omicron is highly transmissible and may cause milder symptoms. Vaccines are less effective against the Omicron variant.

WORLD JOURNAL OF CLINICAL CASES (2022)

Add to Collection

Article Immunology

Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants

Timothy A. Bates et al.

Summary: This study found that individuals who previously recovered from COVID-19 and received vaccination (hybrid immunity) have enhanced immune responses. The effects of post-vaccination breakthrough infections on humoral immune response needs further investigation. However, regardless of whether it occurs before or after vaccination, natural infection substantially boosts the quantity, quality, and breadth of humoral immune response.

SCIENCE IMMUNOLOGY (2022)

Add to Collection

Article Immunology

Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine

Sitthichai Kanokudom et al.

Summary: This study evaluated the booster effect of different vaccine platforms in healthy adults who had received a full dose of inactivated vaccine. The viral vector and mRNA vaccine boosters showed greater immunogenicity compared to the inactivated vaccine. In addition, the vaccinated serum had a high neutralization activity against SARS-CoV-2 wild-type and variants.

VACCINES (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Humoral and cellular immune memory to four COVID-19 vaccines

Zeli Zhang et al.

Summary: Multiple COVID-19 vaccines have successfully protected against symptomatic cases and deaths. Comparisons of T cell, B cell, and antibody responses to different vaccines can provide insights into protective immunity against COVID-19, particularly immune memory. mRNA vaccines and Ad26.COV2.S induced strong T cell responses, while mRNA vaccines showed substantial declines in antibodies.

CELL (2022)

Add to Collection

Review Biotechnology & Applied Microbiology

Therapeutic monoclonal antibodies for COVID-19 management: an update

Vivek P. Chavda et al.

Summary: Monoclonal antibodies are considered the most effective therapy against COVID-19, showing reduction in viral load, hospitalizations, and death rates. Different mAbs are in various stages of clinical trials in different countries, with some already in Phase III and IV.

EXPERT OPINION ON BIOLOGICAL THERAPY (2022)

Add to Collection

Review Pharmacology & Pharmacy

Recent highlights on Omicron as a new SARS-COVID-19 variant: evolution, genetic mutation, and future perspectives

Pooja Khairnar et al.

Summary: COVID-19 has had a significant impact on the world, and the emergence of the Omicron variant has raised global concerns. Vaccination and public health measures remain crucial, and vaccine hesitancy poses a major barrier. This article provides an overview of the SARS-COVID-19 situation, discusses mutational events in different variants, and addresses treatment options and updates on Omicron.

JOURNAL OF DRUG TARGETING (2022)

Add to Collection

Review Virology

SARS-CoV-2 variants and vulnerability at the global level

Vivek P. Chavda et al.

Summary: Numerous variants of SARS-CoV-2 have emerged, with increased transmission, severe illness, evasive immunological features, decreased neutralization by antibodies, and higher susceptibility to reinfection. The CDC has categorized these variants into variants of interest, variants of concern, and variants of high consequence. This review article summarizes the various variants, particularly the globally spreading variants of concern, and their impact on the virus properties.

JOURNAL OF MEDICAL VIROLOGY (2022)

Add to Collection

Letter Virology

The recombinant variants of SARS-CoV-2: Concerns continues amid COVID-19 pandemic

Ranjan K. Mohapatra et al.

JOURNAL OF MEDICAL VIROLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study

Linda-Gail Bekker et al.

LANCET (2022)

Add to Collection

Review Immunology

Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy

Amirmasoud Rayati Damavandi et al.

Summary: The emergence of new variants of SARS-CoV-2 has puzzled scientists and policymakers worldwide. These variants exhibit changes in antigens, including the spike protein, which may affect the virus's ability to bind to receptors. Some variants show higher transmissibility and more severe forms of illness. However, international efforts have been dedicated to developing effective vaccines to combat these variants.

MEDICAL MICROBIOLOGY AND IMMUNOLOGY (2022)

Add to Collection

Editorial Material Biochemistry & Molecular Biology

Boosting immunity to Omicron

Xiaoying Shen

NATURE MEDICINE (2022)

Add to Collection

Review Virology

Present variants of concern and variants of interest of severe acute respiratory syndrome coronavirus 2: Their significant mutations in S-glycoprotein, infectivity, re-infectivity, immune escape and vaccines activity

Chiranjib Chakraborty et al.

Summary: The study discusses the emergence of alarming SARS-CoV-2 variants globally, highlighting key properties, mutations, and clinical characteristics of both variant of concern (VOC) and variant of interest (VOI) variants. The comprehensive review offers updated information on these newly appearing variants to aid researchers in formulating strategies to control the COVID-19 pandemic.

REVIEWS IN MEDICAL VIROLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine

Karen J. Hager et al.

Summary: The CoVLP+AS03 vaccine showed efficacy in preventing Covid-19 caused by different variants, with efficacy ranging from 69.5% against symptomatic infection to 78.8% against moderate-to-severe disease.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Letter Medicine, General & Internal

Neutralization of the SARS-CoV-2 Deltacron and BA.3 Variants

John P. Evans et al.

Summary: The study found that the Delta variant has high resistance to immune responses elicited by vaccines or previous infections, while the BA.3 variant does not show broad cross-resistance.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Cell Biology

mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions

Paulina Kaplonek et al.

Summary: The successful development of COVID-19 vaccines has led to reduced morbidity and mortality. However, the emergence of viral variants has affected the efficacy of the vaccines, showing differences between two approved mRNA platforms, BNT162b2 and mRNA-1273. Understanding the differences in immune responses induced by these vaccines is important for determining their protective immunity.

SCIENCE TRANSLATIONAL MEDICINE (2022)

Add to Collection

Review Virology

Replicating Viral Vector-Based Vaccines for COVID-19: Potential Avenue in Vaccination Arena

Vivek P. Chavda et al.

Summary: This paper discusses the potential of replicating viral vectors as vaccine carriers for SARS-CoV-2. Despite being the third member of human coronaviruses, SARS-CoV-2 has a much wider range of transmission compared to previous coronaviruses. Although there is a possibility of zoonotic origin, no animal originated coronavirus similar to the initial edition of SARS-CoV-2 has been identified so far.

VIRUSES-BASEL (2022)

Add to Collection

Letter Surgery

Hybrid SARS-CoV-2 variants

Farid Rahimi et al.

INTERNATIONAL JOURNAL OF SURGERY (2022)

Add to Collection

Letter Surgery

Recombinant SARS-CoV-2 variants XD, XE, and XF: The emergence of recombinant variants requires an urgent call for research - Correspondence

Chiranjib Chakraborty et al.

INTERNATIONAL JOURNAL OF SURGERY (2022)

Add to Collection

Review Biotechnology & Applied Microbiology

Delta variant (B.1.617.2) of SARS-CoV-2: Mutations, impact, challenges and possible solutions

Manish Dhawan et al.

Summary: The Delta variant, with enhanced transmissibility and decreased vaccine efficacy, poses a challenge in containing the COVID-19 pandemic. Measures are needed to combat the outbreaks caused by novel mutations in the Delta variant.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2022)

Add to Collection

Review Pharmacology & Pharmacy

2-Deoxy-D-Glucose and its Derivatives for the COVID-19 Treatment: An Update

Zoufang Huang et al.

Summary: There is a lack of adequate treatment choices for COVID-19, and no established intervention has effectively reduced mortality rate. Recent studies have shown that 2-deoxy-D-glucose (2-DG) could aid in faster recovery and reduce the need for supplemental oxygen in COVID-19 patients.

FRONTIERS IN PHARMACOLOGY (2022)

Add to Collection

Article Immunology

Is Booster Dose Strategy Sufficient for Omicron Variant of SARS-CoV-2?

Vivek P. Chavda et al.

Summary: The Omicron variant of SARS-CoV-2 is spreading in communities where previous infections and vaccinations have taken place. Over 130 countries have implemented booster dose programs to combat the Omicron variant. While early findings suggest that booster doses may enhance protection against Omicron, further research is needed to determine the efficacy of vaccines. This short communication critically discusses research findings on the booster dose strategy for Omicron.

VACCINES (2022)

Add to Collection

Article Medicine, General & Internal

Durability of the Single-Dose Ad26.COV2.S Vaccine in the Prevention of COVID-19 Infections and Hospitalizations in the US Before and During the Delta Variant Surge

Jennifer M. Polinski et al.

Summary: This cohort study in US clinical practice showed that Ad26.COV2.S vaccine has stable effectiveness for at least 6 months before and during the emergence of the Delta variant, providing protection against COVID-19 infection and hospitalization.

JAMA NETWORK OPEN (2022)

Add to Collection

Article Multidisciplinary Sciences

Machine learning of COVID-19 clinical data identifies population structures with therapeutic potential

David Greenwood et al.

Summary: This study used UMAP and GMM methods to define clusters of COVID-19 patients and identified 29 subgroups with different prognosis. Analysis of clinical features within clusters revealed unexpected relationships between variables. The application of machine learning can assist in delineating disease pathogenesis and potential therapeutic interventions.

ISCIENCE (2022)

Add to Collection

Article Management

Investigating the role of stakeholder engagement for more resilient vaccine supply chains during COVID-19

Yigit Kazancoglu et al.

Summary: The complexity and uncertainties of the supply chains make businesses more vulnerable to disruptions. The COVID-19 pandemic has highlighted the importance of vaccine supply chain management and resilience. The study finds that the innovativeness of stakeholders is the most important factor in stakeholder engagement in vaccine supply chains.

OPERATIONS MANAGEMENT RESEARCH (2022)

Add to Collection

Review Health Policy & Services

Management of COVID-19 vaccines cold chain logistics: a scoping review

Mathumalar Loganathan Fahrni et al.

Summary: This study aimed to synthesize evidence for efficient cold chain management of COVID vaccines. The findings suggest that regulatory requirements, packaging and storage, and transportation and distribution are key factors in the efficient cold chain management. Recommendations were made to improve formulation stability, end-product storage conditions, and monitoring technologies.

JOURNAL OF PHARMACEUTICAL POLICY AND PRACTICE (2022)

Add to Collection

Review Environmental Sciences

Pseudoscience and fraudulent products for COVID-19 management

Vivek P. Chavda et al.

Summary: The COVID-19 pandemic is spreading uncontrollably with new dangerous variants of the virus. Vaccines do not provide complete immunity against these variants. This has led to fear and depression among the public. In response, fraudulent products and remedies claiming to treat the disease have been banned by the FDA. Health agencies should focus on effectiveness and increase awareness and education efforts.

ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH (2022)

Add to Collection

Editorial Material Immunology

Monkeypox: a new face of outbreak

Vivek P. Chavda et al.

EXPERT REVIEW OF VACCINES (2022)

Add to Collection

Editorial Material Immunology

Therapeutics to tackle Omicron outbreak Comment

Vivek P. Chavda et al.

Summary: In this commentary, the authors discuss the mutational impact of the Omicron variant on current therapeutics for managing COVID-19.

IMMUNOTHERAPY (2022)

Add to Collection

Article Virology

Omicron (BA.1) and sub-variants (BA.1.1, BA.2, and BA.3) of SARS-CoV-2 spike infectivity and pathogenicity: A comparative sequence and structural-based computational assessment

Suresh Kumar et al.

Summary: This study used computational tools to evaluate the infectivity, transmission, and pathogenicity of the Omicron variant and its sub-variants. The research found that the Omicron and sub-variants have multiple mutations in the receptor-binding domain, increasing their affinity for human ACE2 and potential for transmission. However, mutations in the spike protein's N-terminal domain may result in less impact on the lower respiratory tract. Some mutations in the sub-variants of Omicron seemed to restore the binding effectiveness to ACE2.

JOURNAL OF MEDICAL VIROLOGY (2022)

Add to Collection

Article Infectious Diseases

Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial

Raburn M. Mallory et al.

Summary: This study assessed the immunogenicity and safety of a booster dose of a SARS-CoV-2 recombinant spike protein vaccine. The results showed that the immune responses following the booster were similar to or higher than those associated with high levels of efficacy in phase 3 studies, supporting the use of this vaccine in booster programs.

LANCET INFECTIOUS DISEASES (2022)

Add to Collection

Article Infectious Diseases

Global impact of the first year of COVID-19 vaccination: a mathematical modelling study

Oliver J. Watson et al.

Summary: A study quantified the global impact of the first year of COVID-19 vaccination programs, finding that the vaccination has substantially altered the course of the pandemic, saving tens of millions of lives globally. However, inadequate access to vaccines in low-income countries has limited the impact, reinforcing the need for global vaccine equity and coverage.

LANCET INFECTIOUS DISEASES (2022)

Add to Collection

Letter Medicine, General & Internal

A Zoonotic Henipavirus in Febrile Patients in China

Xiao-Ai Zhang et al.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Immunology

Inhalable Vaccines: Can They Help Control Pandemics?

Vivek P. Chavda et al.

Summary: The emergence of a new coronavirus poses a significant risk to global public health and has resulted in the continual evolution and emergence of new viral variants, challenging existing strategies for COVID-19 management and vaccine efficacy. To interrupt viral spread, it is crucial to protect the respiratory tract and advocate the use of pulmonary/inhalable vaccines.

VACCINES (2022)

Add to Collection

Review Immunology

COVID-19 and vaccination: myths vs science

Vivek P. Chavda et al.

Summary: The development of COVID-19 vaccines has been rapid, but concerns and misinformation surrounding their efficacy and safety need to be addressed critically. While many questions regarding COVID-19 and its vaccines have been answered with scientific evidence, there are still myths and misinformation that contribute to vaccine hesitancy.

EXPERT REVIEW OF VACCINES (2022)

Add to Collection

Editorial Material Geriatrics & Gerontology

Rare monkeypox: Is it really a threat to the elderly?

Vivek P. Chavda et al.

MATURITAS (2022)

Add to Collection

Letter Infectious Diseases

Emergence of omicron variant's sublineages BA.4 and BA.5: risks assessment and possible countermeasures

Manish Dhawan et al.

NEW MICROBES AND NEW INFECTIONS (2022)

Add to Collection

Article Infectious Diseases

Global impact of the first year of COVID-19 vaccination: a mathematical modelling study

Oliver J. Watson et al.

Summary: The study estimated that COVID-19 vaccination has prevented millions of deaths globally between December 8, 2020, and December 8, 2021. Achieving the vaccination coverage targets set by COVAX and WHO could have prevented even more deaths. However, limited access to vaccines in low-income countries has hindered the impact, highlighting the importance of global vaccine equity.

LANCET INFECTIOUS DISEASES (2022)

Add to Collection

Review Virology

Severe acute respiratory syndrome-coronavirus-2 spike (S) protein based vaccine candidates: State of the art and future prospects

Arash Arashkia et al.

Summary: COVID-19 is caused by SARS-CoV-2 and an urgent need for the development of a safe and effective vaccine exists to prevent global spread. The spike (S) protein of SARS-CoV-2 plays a crucial role in cell entry and is a key target for vaccine development to induce protective immunity.

REVIEWS IN MEDICAL VIROLOGY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

COVID-19 vaccines: where we stand and challenges ahead

Guido Forni et al.

Summary: The development of vaccines has made significant progress, but still faces various challenges, including different target populations, immunological adaptability of vaccines, and production and distribution issues. To ensure equitable access, protection of diverse subjects, and immunity against viral variants, multiple vaccines may be needed in the long run.

CELL DEATH AND DIFFERENTIATION (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Can SARS-CoV-2 Virus Use Multiple Receptors to Enter Host Cells?

Laura Kate Gadanec et al.

Summary: The S protein of SARS-CoV-2 may exploit multiple receptors for infection and interact with both immune and non-immune cells through C-lectin type receptors (CLR), toll-like receptors (TLR), neuropilin-1 (NRP1), and glucose regulated protein 78 (GRP78), potentially driving severe immunopathological inflammation and facilitating systemic spread of infection. Targeting these receptors, as well as other receptors such as Toll-like receptors (TLRs), CLR, Ezrin, and dipeptidyl peptidase-4, could provide therapeutic targets against COVID-19 by enhancing anti-viral immunity and viral clearance.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Genetic Variants of SARS-CoV-2-What Do They Mean?

Adam S. Lauring et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Jordan R. Barrett et al.

Summary: The study demonstrates that a booster dose of ChAdOx1 nCoV-19 is safer and better tolerated than priming doses. The booster dose significantly enhances anti-spike neutralizing antibody titers and other functional antibody responses. These data support the two-dose vaccine regime currently being evaluated in phase 3 clinical trials.

NATURE MEDICINE (2021)

Add to Collection

Article Infectious Diseases

Introduction and rapid dissemination of SARS-CoV-2 Gamma Variant of Concern in Venezuela

Rossana C. Jaspe et al.

Summary: The study aimed to monitor the introduction of variants and VOCs in Venezuela, with the detection of the Gamma VOC since January 2021, which became predominant in the country by March 2021. Additionally, other isolates carrying the E484K mutation were also detected.

INFECTION GENETICS AND EVOLUTION (2021)

Add to Collection

Review Physiology

Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections?

Varnica Bajaj et al.

Summary: The novel coronavirus has greatly impacted the world with over 72 million cases and 1.6 million deaths, mostly affecting the elderly population. Aging leads to changes in the immune system, making elderly individuals more susceptible to infections and less responsive to vaccines. Understanding age-related immune system changes is crucial for managing infectious diseases like COVID-19.

FRONTIERS IN PHYSIOLOGY (2021)

Add to Collection

Review Pharmacology & Pharmacy

COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies

Kajal Rawat et al.

Summary: COVID-19, caused by a new strain of betacoronavirus named as SARS-CoV-2, poses a huge burden on public health and global economies due to its high transmission rate. Developing vaccines is essential for preventing the spread of the virus and reducing mortality.

EUROPEAN JOURNAL OF PHARMACOLOGY (2021)

Add to Collection

Editorial Material Microbiology

Dual targeting of toll-like receptor 4 and angiotensin-converting enzyme 2: a proposed approach to SARS-CoV-2 treatment

Laura Kate Gadanec et al.

FUTURE MICROBIOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors

Rachna T. Shroff et al.

Summary: Cancer patients showed diminished immune responses to the BNT162b2 mRNA vaccine compared to the control group, but a third dose of the vaccine was found to be safe and significantly improved humoral immunity against SARS-CoV-2.

NATURE MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Merryn Voysey et al.

Summary: The AZD1222 vaccine has been approved for emergency use in the UK with an interval of 4-12 weeks between doses. Analysis shows that the vaccine is efficacious with two doses and provides immunoprotection after the first dose before the second dose is administered.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial

Peter Richmond et al.

Summary: A study in Australia evaluated the dose-finding and adjuvant justification of the SCB-2019 vaccine against SARS-CoV-2. The vaccine, which contains a stabilised trimeric form of the spike protein (S-Trimer) combined with AS03 or CpG/Alum adjuvants, elicited robust humoral and cellular immune responses in both younger and older adults.

LANCET (2021)

Add to Collection

Article Multidisciplinary Sciences

S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates

Joshua G. Liang et al.

Summary: Researchers have developed a trimeric vaccine candidate S-Trimer for COVID-19 based on Trimer-Tag technology. Immunization studies in animal models showed high levels of neutralizing antibodies and cellular immune responses, and protection from SARS-CoV-2 challenge in rhesus macaques. This technology may be crucial for scalable production of subunit vaccines against emerging RNA viruses.

NATURE COMMUNICATIONS (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Covid-19: India is at centre of global vaccine manufacturing, but opacity threatens public trust

Kamala Thiagarajan

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Article Genetics & Heredity

Effect of An 84-bp Deletion of the Receptor-Binding Domain on the ACE2 Binding Affinity of the SARS-CoV-2 Spike Protein: An In Silico Analysis

Gabor Kemenesi et al.

Summary: In this study, a co-infection of two genetically different SARS-CoV-2 viruses within a single patient was identified in Hungary, with one strain containing an 84-base pair deletion in the Spike protein gene. The recessive variant was gradually replaced by a dominant non-deleterious variant over time. The mutation in the receptor binding domain of the Spike protein gene was suggested to have a negative effect on the binding of RBD to the ACE2 receptor, leading to the negative selection of the variant.

GENES (2021)

Add to Collection

Review Immunology

SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates

Nikolaos C. Kyriakidis et al.

Summary: The new SARS-CoV-2 virus is rapidly spreading worldwide, causing the COVID-19 pandemic with more than 1.866 million deaths. Over 64 vaccine candidates are being developed globally, aiming to induce antibodies to prevent viral entry. Thirteen vaccine candidates are currently in Phase 3 clinical trials, showing promising progress towards approval for large-scale immunizations.

NPJ VACCINES (2021)

Add to Collection

Article Medicine, General & Internal

Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study

Katia J. Bruxvoort et al.

Summary: The study evaluated the effectiveness of mRNA-1273 vaccine against SARS-CoV-2 variants, especially the delta variant, by time since vaccination. Two doses of the vaccine showed high effectiveness against all variants, with a decline in effectiveness against delta variant over time. One dose of the vaccine also demonstrated moderate effectiveness against delta infection.

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Article Genetics & Heredity

Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants

Chunyan Yi et al.

Summary: This study identified 33 amino acid positions within four independent antigenic sites of RBD as valuable indicators of antigenic changes. The research confirms widely circulating strains carrying important immune-escape RBD mutations, while also uncovering new immune escape-enabling mutations. Co-mutations may lead to increased resistance to NAbs and convalescent plasma, emphasizing the importance of monitoring the accumulation of co-mutations on distinct major antigenic sites.

GENOME MEDICINE (2021)

Add to Collection

Article Infectious Diseases

Effectiveness of the Comirnaty (BNT162b2, BioNTech/Pfizer) vaccine in preventing SARS-CoV-2 infection among healthcare workers, Treviso province, Veneto region, Italy, 27 December 2020 to 24 March 2021

Massimo Fabiani et al.

Summary: A study conducted in Italy showed that the BioNTech/Pfizer COVID-19 vaccine has an effectiveness of 84% and 95% in preventing SARS-CoV-2 infection within certain time intervals, supporting ongoing vaccination campaigns with targeted communication.

EUROSURVEILLANCE (2021)

Add to Collection

Review Immunology

Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies

Lianlian Bian et al.

Summary: The global spread of the SARS-CoV-2 pandemic has led to the emergence of several variants, posing challenges to vaccine efficacy. However, some vaccines have shown advantages in providing protection against certain variants. Response strategies have been proposed to address the challenges posed by emerging variants, including accelerating the rollout of current vaccines, enhancing vaccine immunogenicity, and developing next-generation vaccines targeting the variants.

EXPERT REVIEW OF VACCINES (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Enhanced binding of the N501Y-mutated SARS-CoV-2 spike protein to the human ACE2 receptor: insights from molecular dynamics simulations

Binquan Luan et al.

Summary: Recently emerged SARS-CoV-2 variants with mutations, such as N501Y, may enhance binding to hACE2. Molecular dynamics simulations show that Y501 in the mutated RBD can interact with Y41 and K353 in hACE2, potentially increasing the overall binding affinity by approximately 0.81 kcal center dot mol(-1). This binding dynamics may aid in designing more effective antibodies.

FEBS LETTERS (2021)

Add to Collection

Letter Public, Environmental & Occupational Health

Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2

Gajanan N. Sapkal et al.

JOURNAL OF TRAVEL MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

Katherine R. W. Emary et al.

Summary: A post-hoc analysis was conducted on the efficacy of the ChAdOx1 nCoV-19 vaccine against the B.1.1.7 variant of SARS-CoV-2 in the UK. The vaccine showed reduced neutralisation activity against the B.1.1.7 variant in vitro, but still demonstrated efficacy against the B.1.1.7 variant of the virus.

LANCET (2021)

Add to Collection

Article Infectious Diseases

Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials

Shilong Yang et al.

Summary: The results from Phase 1 and Phase 2 trials of the COVID-19 vaccine ZF2001 show that the vaccine is well tolerated and immunogenic, supporting the use of a 25 microgram dose in a three-dose schedule for large-scale evaluation in a Phase 3 trial.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Article Infectious Diseases

Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study

Cristina Menni et al.

Summary: This study investigated the safety and effectiveness of the BNT162b2 and ChAdOx1 nCoV-19 vaccines in a UK community setting. The results showed that the frequencies of side effects from these vaccines were lower than reported in clinical trials, and a significant reduction in the risk of SARS-CoV-2 infection was observed starting at 12 days after vaccination.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Article Medicine, General & Internal

Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination

Marie Scully et al.

Summary: 23 cases of thrombotic thrombocytopenia were reported after receiving the AstraZeneca vaccine, incited by antibodies to platelet factor 4 and unrelated to heparin therapy. Avoidance of platelet transfusion and consideration of nonheparin anticoagulant and intravenous immune globulin are recommended for treatment.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Editorial Material Medicine, General & Internal

SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia

Douglas B. Cines et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Infectious Diseases

The impact of spike mutated variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccines

Mehrdad Mohammadi et al.

Summary: This review discusses the impact of spike mutated variants of SARS-CoV2 (Alpha, Beta, Gamma, Delta, and Lambda) on the efficacy of subunit recombinant vaccines. To date, there have been reports of low or no significant impact on vaccine efficacy against Alpha and Delta variants. However, impacts on vaccine efficacy for Beta, Gamma, Delta, and Lambda variants may be even greater, requiring more comprehensive analyses to assess the real impact on vaccine efficacy brought about by SARS-CoV-2 variants.

BRAZILIAN JOURNAL OF INFECTIOUS DISEASES (2021)

Add to Collection

Editorial Material Immunology

Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination

Swantje I. Hammerschmidt et al.

CELLULAR & MOLECULAR IMMUNOLOGY (2021)

Add to Collection

Review Pharmacology & Pharmacy

Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management

Vivek P. Chavda et al.

Summary: Intranasal vaccines have advantages in targeting SARS-CoV-2 infection, eliciting immune responses, and avoiding infections, while also convenient for self-administration and storage at ambient temperatures.

DRUG DISCOVERY TODAY (2021)

Add to Collection

Article Medicine, General & Internal

Surveillance for Adverse Events After COVID-19 mRNA Vaccination

Nicola P. Klein et al.

Summary: This study conducted interim analysis of safety surveillance data of mRNA COVID-19 vaccines and found that the incidence of selected serious outcomes within 1-21 days post-vaccination was not significantly higher compared with 22-42 days post-vaccination. Surveillance is ongoing despite wide confidence intervals for many outcomes.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Medicine, General & Internal

Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults A Randomized Clinical Trial

Nawal Al Kaabi et al.

Summary: This interim analysis of an ongoing randomized trial in the UAE and Bahrain evaluated the efficacy of two inactivated COVID-19 vaccines in preventing symptomatic cases and adverse events in healthy adults. The study found that both vaccines significantly reduced the risk of symptomatic COVID-19 compared to the control group, with efficacy rates of 72.8% and 78.1%. Serious adverse events were rare across all groups.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination

Joana Barros-Martins et al.

Summary: A study found that booster vaccination with BNT162b2 in healthcare professionals previously vaccinated with ChAdOx-1 nCoV-19 elicited more neutralizing antibodies and higher frequencies of virus-specific T cells. Additionally, BNT162b2 induced high titers of neutralizing antibodies against variants of concern, such as B.1.1.7, B.1.351, and P.1.

NATURE MEDICINE (2021)

Add to Collection

Review Microbiology

SARS-CoV-2 variants, spike mutations and immune escape

William T. Harvey et al.

Summary: The evolution of SARS-CoV-2 has been characterized by the emergence of mutations and variants that impact virus characteristics. Manufacturers are preparing for possible updates to vaccines in response to changes in the virus population, and it is crucial to monitor genetic and antigenic changes alongside experiments to understand the impacts of mutations.

NATURE REVIEWS MICROBIOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

Paul T. Heath et al.

Summary: The NVX-CoV2373 vaccine demonstrated an efficacy of 89.7% in a phase 3 trial with over 15,000 participants, with mild and transient reactogenicity. It showed high efficacy against the B.1.1.7 variant and a low incidence of adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination

Johan Normark et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Immunology

Crucial Mutations of Spike Protein on SARS-CoV-2 Evolved to Variant Strains Escaping Neutralization of Convalescent Plasmas and RBD-Specific Monoclonal Antibodies

Chengchao Ding et al.

Summary: Research has found that certain key mutations in the spike protein of SARS-CoV-2 may lead to the virus evading neutralization by convalescent plasmas and monoclonal antibodies.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Immunology

Vaccine Passports May Backfire: Findings from a Cross-Sectional Study in the UK and Israel on Willingness to Get Vaccinated against COVID-19

Talya Porat et al.

Summary: The study found that autonomy frustration is associated with lower willingness to get vaccinated and a shift from self-determined to external motivation. In Israel, a country with vaccine passports, people reported greater autonomy frustration compared to the UK, a country without vaccine passports.

VACCINES (2021)

Add to Collection

Article Health Care Sciences & Services

An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine Sputnik Light for prevention of coronavirus infection in healthy adults

Amir Tukhvatulin et al.

Summary: A study conducted in Russia indicates that the newly developed single-dose vaccine Sputnik Light demonstrates good safety and immunogenicity against COVID-19, significantly boosting antibody levels and eliciting positive responses at the immune cell level.

LANCET REGIONAL HEALTH-EUROPE (2021)

Add to Collection

Article Chemistry, Medicinal

Darunavir ethanolate: Repurposing an anti-HIV drug in COVID-19 treatment

Vivek P. Chavda et al.

Summary: Antivirals and knowledge from previous outbreaks like SARS and MERS are considered the most effective way to combat the coronavirus outbreak, especially with the considerable mortality caused by SARS-CoV-2. The ongoing viral mutations have led to different waves of SARS-CoV-2, highlighting the need for effective therapies and antivirals.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY REPORTS (2021)

Add to Collection

Article Immunology

Immunological mechanisms of vaccine-induced protection against COVID-19 in humans

Manish Sadarangani et al.

Summary: Most COVID-19 vaccines aim to induce immune responses, particularly neutralizing antibodies (NAbs), against the spike protein of the virus. mRNA vaccines have shown efficacy after just one dose, while adenovirus vaccines elicit polyfunctional antibodies and strong T cell responses. These findings suggest that protection may not solely rely on NAbs but also involve other immune effector mechanisms.

NATURE REVIEWS IMMUNOLOGY (2021)

Add to Collection

Review Multidisciplinary Sciences

Current progress and challenges in the design and development of a successful COVID-19 vaccine

Tingting Li et al.

Summary: With over 200 COVID-19 vaccine candidates currently in development, there are numerous scientific and practical challenges that need to be addressed. The successful design of a vaccine is essential for effectively combating the pandemic.

FUNDAMENTAL RESEARCH (2021)

Add to Collection

Review Microbiology

COVID-19: Diagnostics, Therapeutic Advances, and Vaccine Development

Sabhiya Majid et al.

Summary: This review highlights the efforts of healthcare workers and the scientific community in successfully tackling the COVID-19 pandemic, despite the serious impacts in terms of severe illness, loss of lives, and livelihood. Extensive research has focused on therapeutic options, antiviral strategies, diagnostic options, and the remarkable vaccine development process.

CURRENT CLINICAL MICROBIOLOGY REPORTS (2021)

Add to Collection

Review Immunology

A guide to vaccinology: from basic principles to new developments

Andrew J. Pollard et al.

Summary: Immunization is vital for public health policy and there are challenges ahead for immunologists in developing new vaccines. Although immunology has not contributed significantly to vaccine development so far, a better understanding of protective immunity is urgently needed to tackle difficult-to-target pathogens.

NATURE REVIEWS IMMUNOLOGY (2021)

Add to Collection

Review Immunology

Viral targets for vaccines against COVID-19

Lianpan Dai et al.

Summary: The urgent need for vaccines to control the COVID-19 pandemic has led to the rapid development of multiple vaccine candidates, with some showing positive results in late-stage clinical trials. This article discusses the viral elements used in these candidates, the reasons why they are good targets for the immune system, and their implications for protective immunity. Dai and Gao highlight the importance of selecting the right viral targets in vaccine development to ensure an effective immune response and the overall safety and efficacy of the vaccine.

NATURE REVIEWS IMMUNOLOGY (2021)

Add to Collection

Review Public, Environmental & Occupational Health

Remdesivir and its antiviral activity against COVID-19: A systematic review

Andri Frediansyah et al.

Summary: Remdesivir exhibits potent antiviral activities against SARS-CoV-2 and has shown efficacy in treating COVID-19 patients in clinical practice, but further efficacy assessments in clinical trials are needed.

CLINICAL EPIDEMIOLOGY AND GLOBAL HEALTH (2021)

Add to Collection

Review Immunology

The promise of mRNA vaccines: a biotech and industrial perspective

Nicholas A. C. Jackson et al.

NPJ VACCINES (2020)

Add to Collection

Review Cell Biology

Why does COVID-19 disproportionately affect older people?

Amber L. Mueller et al.

AGING-US (2020)

Add to Collection

Editorial Material Biochemical Research Methods

Progress and Concept for COVID-19 Vaccine Development

Suh-Chin Wu

BIOTECHNOLOGY JOURNAL (2020)

Add to Collection

Review Biochemistry & Molecular Biology

Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19

Gregory D. Sempowski et al.

CELL (2020)

Add to Collection

Review Microbiology

Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses

Ning Wang et al.

FRONTIERS IN MICROBIOLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

Xiuyuan Ou et al.

NATURE COMMUNICATIONS (2020)

Add to Collection

Article Public, Environmental & Occupational Health

Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) - United States, February 12-March 16, 2020

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2020)

Add to Collection

Review Cardiac & Cardiovascular Systems

A Review of Remdesivir for COVID-19: Data to Date

Monica Mehta et al.

CARDIOLOGY IN REVIEW (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2

Hui Wang et al.

CELL (2020)

Add to Collection

Letter Virology

The Nucleocapsid Protein of SARS-CoV-2: a Target for Vaccine Development

Noton K. Dutta et al.

JOURNAL OF VIROLOGY (2020)

Add to Collection

Editorial Material Chemistry, Physical

Next-generation vaccine platforms for COVID-19

Debby van Riel et al.

NATURE MATERIALS (2020)

Add to Collection

Editorial Material Medicine, General & Internal

Emergency Use Authorization of Covid Vaccines - Safety and Efficacy Follow-up Considerations

Philip R. Krause et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

E. J. Anderson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Review Multidisciplinary Sciences

A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity

Angkana T. Huang et al.

NATURE COMMUNICATIONS (2020)

Add to Collection

Article Multidisciplinary Sciences

Sequence analysis of SARS-CoV-2 genome reveals features important for vaccine design

Jacob Kames et al.

SCIENTIFIC REPORTS (2020)

Add to Collection

Review Pharmacology & Pharmacy

Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19

Rudra P. Saha et al.

FRONTIERS IN PHARMACOLOGY (2020)

Add to Collection

Review Immunology

A Review of the Progress and Challenges of Developing a Vaccine for COVID-19

Omna Sharma et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Editorial Material Biochemistry & Molecular Biology

A Possible Path towards Rapid Development of Live-Attenuated SARS-CoV-2 Vaccines: Plunging into the Natural Pool

German Todorov et al.

BIOMOLECULES (2020)

Add to Collection

Article Immunology

Innate Immune Responses to Chimpanzee Adenovirus Vector 155 Vaccination in Mice and Monkeys

Catherine Collignon et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Limitations of Animal Studies for Predicting Toxicity in Clinical Trials Part 2: Potential Alternatives to the Use of Animals in Preclinical Trials

Gail A. Van Norman

JACC-BASIC TO TRANSLATIONAL SCIENCE (2020)

Add to Collection

Review Endocrinology & Metabolism

Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies

Awadhesh Kumar Singh et al.

DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2020)

Add to Collection

Review Ophthalmology

Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future

Rohit Shetty et al.

INDIAN JOURNAL OF OPHTHALMOLOGY (2020)

Add to Collection

Article Immunology

New Vaccine Design and Delivery Technologies

Masaru Kanekiyo et al.

JOURNAL OF INFECTIOUS DISEASES (2019)

Add to Collection

Review Biotechnology & Applied Microbiology

mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases

Giulietta Maruggi et al.

MOLECULAR THERAPY (2019)

Add to Collection

Correction Biochemical Research Methods

Emerging Technologies for Low-Cost, Rapid Vaccine Manufacture (vol 14, 1800376, 2019)

Zoltan Kis et al.

BIOTECHNOLOGY JOURNAL (2019)

Add to Collection

Article Virology

Combination Attenuation Offers Strategy for Live Attenuated Coronavirus Vaccines

Vineet D. Menachery et al.

JOURNAL OF VIROLOGY (2018)

Add to Collection

Review Biotechnology & Applied Microbiology

mRNA vaccines - a new era in vaccinology

Norbert Pardi et al.

NATURE REVIEWS DRUG DISCOVERY (2018)

Add to Collection

Review Virology

MERS-CoV: Understanding the Latest Human Coronavirus Threat

Aasiyah Chafekar et al.

VIRUSES-BASEL (2018)

Add to Collection

Review Biochemistry & Molecular Biology

Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems

S. Guan et al.

GENE THERAPY (2017)

Add to Collection

Review Virology

Targeting Pattern Recognition Receptors (PRR) for Vaccine Adjuvantation: From Synthetic PRR Agonists to the Potential of Defective Interfering Particles of Viruses

Andri Vasou et al.

VIRUSES-BASEL (2017)

Add to Collection

Article Chemistry, Multidisciplinary

Materials for non-viral intracellular delivery of messenger RNA therapeutics

Kevin J. Kauffman et al.

JOURNAL OF CONTROLLED RELEASE (2016)

Add to Collection

Review Biotechnology & Applied Microbiology

Coronaviruses - drug discovery and therapeutic options

Alimuddin Zumla et al.

NATURE REVIEWS DRUG DISCOVERY (2016)

Add to Collection

Article Biotechnology & Applied Microbiology

Prospects for subunit vaccines: Technology advances resulting in efficacious antigens requires matching advances in early clinical trial investment

Siobhan McClean

Human Vaccines & Immunotherapeutics (2016)

Add to Collection

Article Biotechnology & Applied Microbiology

Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals

Andreas Thess et al.

MOLECULAR THERAPY (2015)

Add to Collection

Review Biochemistry & Molecular Biology

Cell Therapy Strategies to Combat Immunosenescence

Elizabeth C. Stahl et al.

ORGANOGENESIS (2015)

Add to Collection

Review Immunology

Inactivated virus vaccines from chemistry to prophylaxis: merits, risks and challenges

Iris Delrue et al.

EXPERT REVIEW OF VACCINES (2012)

Add to Collection

Review Cell Biology

Return of inactivated whole-virus vaccine for superior efficacy

Yoichi Furuya

IMMUNOLOGY AND CELL BIOLOGY (2012)

Add to Collection

Article Biochemistry & Molecular Biology

A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease

Rachel L. Graham et al.

NATURE MEDICINE (2012)

Add to Collection

Article Virology

A Double-Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine Provides Incomplete Protection in Mice and Induces Increased Eosinophilic Proinflammatory Pulmonary Response

Meagan Bolles et al.

JOURNAL OF VIROLOGY (2011)

Add to Collection

Article Biochemistry & Molecular Biology

Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA

Katalin Kariko et al.

NUCLEIC ACIDS RESEARCH (2011)

Add to Collection

Review Biotechnology & Applied Microbiology

Rationalizing the development of live attenuated virus vaccines

Adam S. Lauring et al.

NATURE BIOTECHNOLOGY (2010)

Add to Collection

Article Biotechnology & Applied Microbiology

Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability

Katalin Kariko et al.

MOLECULAR THERAPY (2008)

Add to Collection

Article Biotechnology & Applied Microbiology

Type I interferon inhibits antibody responses induced by a chimpanzee adenovirus vector

Scott E. Hensley et al.

MOLECULAR THERAPY (2007)

Add to Collection

Article Immunology

A double-inactivated whole virus candidate SARS coronavirus vaccine

M Spruth et al.

VACCINE (2006)

Add to Collection

Article Virology

New viral vaccines

AM Arvin et al.

VIROLOGY (2006)

Add to Collection

© Peeref 2019-2024. All rights reserved.